DOI: http://dx.doi.org/10.18203/2349-3933.ijam20192252

Association of high-density lipoprotein and myocardial infarction: a cross sectional study

Siraveni Thirupathi, Chinnaiyan P., Sujeetha Chandrababu

Abstract


Background: There is substantial evidence illustrating a negative relationship between High Density Lipoprotein Cholesterol (HDL-C) to Coronary Artery Disease (CAD) progression. HDL concept can be put forward as a new concept in the field of cardiovascular research. The objective of this study was to carry out to observe the status of serum HDL-C level in Coronary Artery Disease patients and the impact of the level in them.

Methods: It was a hospital based cross sectional observational study among 60 patients of acute myocardial infarction (MI) who were admitted in Medical intensive care unit. High density lipoprotein cholesterol (HDL-C) was determined using standard methods.

Results: The study showed that 52 (86.7%) of study subjects had abnormal HDL-C level and 39 (65%) of subjects had abnormal CRP level. There is a negative correlation between HDL and other biochemical variables like LDL, LDL/HDL and CRP, i.e. as HDL decreases all the variables increase which is statistically significant. Majority of patients 52 (86.7%) with MI had abnormal HDL-C level which was not statistically significant.

Conclusions: Numerous studies showing evidence that high levels of HDL-Cholesterol associated with a lower risk of Coronary heart disease. This study showed that there is a low HDL-C level among coronary artery disease patient. The relationship between HDL and CAD proved to be an inverse one which caters the need to concentrate further on HDL.


Keywords


Coronary artery diseases, Cross sectional study, HDL

Full Text:

PDF

References


Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71.

Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nature Reviews Cardiology. 2014 May;11(5):276.

Mendis S, Puska P, Norrving B, World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.

Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97(6):596-601.

Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, Ounpuu S, Yusuf S. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation. 2005 Dec 6;112(23):3554-61.

Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 2000 Dec 1;153(2):263-72.

Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 May 16; 285(19):2486.

Ballantyne CM, Herd JA, Ferlic LL. Influence of low HDL-C on progression of coronary artery disease and response to Fluvastatine therapy. Circulation. 1999;99:85-8.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79(1):8-15.

Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circulation research. 2004 Oct 15;95(8):764-72.

Nofer JR, Van Der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P 3. J Clin Investigation. 2004 Feb 15;113(4):569-81.

Rye KA, Barter PJ. Anti-inflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1890-1.

Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications. 2000;14(3):154-74.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.

Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis Thromb Vas Biol. 1997 Jun 1;17(6):1121-7.

da Silva PM, Duarte JS, von Hafe P, Gil V, de Oliveira JN, de Sousa G. Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines-full report. Atherosclerosis Supplements. 2018 Jun 30;31:e1-2.

Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart J. 2015 Jun 1;67(2):89-97.

Rahman MA, Ali MA, Majumdar AAS, Haque KMHSS, Banoo H & Zaman MA. Dyslipidaemia and coronary artery disease. Bangladesh Heart J. 2001;18(1):30-35.

Gupta R, Vasisht S, Bahl VK, Wasir HS. Correlation of lipoprotein (a) to angiographically defined coronary artery disease in Indians. Int J Cardiol. 1996;57:265-70.

Mohan V, Deepa R, Rani SS, Premalatha G, Chennai Urban Population Study (CUPS No. 5). Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai urban population study (CUPS No. 5). J Am Coll Cardiol. 2001;38(3):682-7.

Arca M, Montali A, Valiante S, Campagna F, Pigna G, Paoletti V, et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol. 2007;100(10):1511-6.

Sharma SB, Garg S, Veerwal A, Dwivedi S. hs-CRP and oxidative stress in young CAD patients: A pilot study. Indian J Clin Biochem. 2008;23(4):334-6.

Uddin MK, Ahmed F, Hossain MK, Khatun M, Meah MM. High Density Lipoprotein Cholesterol (HDL-C) Status in Patients of Acute ST-Elevation Myocardial Infarction (STEMI). Chattagram Maa-O-Shishu Hosp Med Coll J. 2017;16(1):11-4.

Mohan V, Deepa R. Risk factors for coronary artery diseases in Indians. J Assoc Physicians India. 2004;52:95-7.

Rissam HS, Kishore S, Trehan N. Coronary artery disease in young Indians-the missing link. J Indian Acad Clin Med. 2001 Jul;2(3):128-31.

Ramirez A, Hu PP. Low high-density lipoprotein and risk of myocardial infarction. Clin Med Insights: Cardiol. 2015;9:CMC-S26624.

Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C‐reactive protein and coronary heart disease: a critical review. J Inter Med. 2008 Oct;264(4):295-314.

Strang F, Schunkert H. C-reactive protein and coronary heart disease: all said-is not it?. Mediators Inflammation. 2014;2014:1-7.